Floatz logo

cd34+ enriched, t cell depleted donor stem cell product

Bone Marrow Failure

Cell therapyDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

26 Active assets in the Bone Marrow Failure cohort.

Asset / SponsorPhaseRating
Fludarabine
Fred Hutchinson Cancer Center
Phase 2/3BBB
Cyclophosphamide
Memorial Sloan Kettering Cancer Center
Phase 2/3BBB
Thiotepa
Fred Hutchinson Cancer Center
Phase 2BB
IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2/3BB
Busulphan
Memorial Sloan Kettering Cancer Center
Phase 2/3BB

View all 37 →

Same molecule, other indications

cd34+ enriched, t cell depleted donor stem cell product is also rated in:

myelodysplastic syndromeDormant
D
Indicative ·
30 / 100
View asset →
chronic myeloid leukemiaDormant
D
Indicative ·
30 / 100
View asset →
lymphomaDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →